Recombinant human parathyroid hormone, sold under the brand names Preotact and Natpara, is an artificially manufactured form of the parathyroid hormone used to treat hypoparathyroidism. Recombinant human parathyroid hormone is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures. A significant reduction in the incidence of vertebral fractures has been demonstrated.The most common side effects include sensations of tingling, tickling, pricking, or burning of the skin (paraesthesia); low blood calcium; headache; high blood calcium; and nausea. Medical uses
Natpara is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in people with hypoparathyroidism.Preotact was approved by the European Medicines Agency for the treatment of osteoporosis in postmenopausal women at high risk of fractures, but the marketing authorisation has been withdrawn at the manufacturers request. Administration
The recommended dose is 100 micrograms of Preotact administered once-daily as a subcutaneous injection into the abdomen, during 18 months (data support treatment up to 24 months). The injections are given using a specially designed injection device (Preotact(TM)Pen). The PreotactPen is specifically designed to allow osteoporosis patients to administer the injections, despite challenges of vision impairment and limited strength of hands and digits tributable to high age. Patients should receive supplemental calcium and vitamin D during treatment with parathyroid hormone.
Dasiglucagon, sold under the brand name Zegalogue, is a medication used to treat severe hypoglycemia in people with diabetes.The most common side effects include nausea, vomiting, headache, diarrhea, and injection site pain.Dasiglucagon was approved for medical use in the United States in March 2021. It was designated an orphan drug in August 2017. Medical uses
Dasiglucagon is indicated for the treatment of severe hypoglycemia in people aged six years of age and older with diabetes. Contraindications
Dasiglucagon is contraindicated in people with pheochromocytoma or insulinoma. References
External links
"Dasiglucagon". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT03378635 for "A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects" at ClinicalTrials.gov
Clinical trial number NCT03688711 for "Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM" at ClinicalTrials.gov
Clinical trial number NCT03667053 for "Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children" at ClinicalTrials.gov